Literature DB >> 16913164

Antidepressant discontinuation syndrome.

Christopher H Warner1, William Bobo, Carolynn Warner, Sara Reid, James Rachal.   

Abstract

Antidepressant discontinuation syndrome occurs in approximately 20 percent of patients after abrupt discontinuation of an antidepressant medication that was taken for at least six weeks. Typical symptoms of antidepressant discontinuation syndrome include flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, and hyperarousal. These symptoms usually are mild, last one to two weeks, and are rapidly extinguished with reinstitution of antidepressant medication. Antidepressant discontinuation syndrome is more likely with a longer duration of treatment and a shorter half-life of the treatment drug. A high index of suspicion should be maintained for the emergence of discontinuation symptoms, which should prompt close questioning regarding accidental or purposeful self-discontinuation of medication. Before antidepressants are prescribed, patient education should include warnings about the potential problems associated with abrupt discontinuation. Education about this common and likely underrecognized clinical phenomenon will help prevent future episodes and minimize the risk of misdiagnosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16913164

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  32 in total

1.  SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents.

Authors:  Sheik Hosenbocus; Raj Chahal
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2011-02

2.  Antidepressant discontinuation syndrome.

Authors:  Matthew Gabriel; Verinder Sharma
Journal:  CMAJ       Date:  2017-05-29       Impact factor: 8.262

Review 3.  Subtherapeutic doses of SSRI antidepressants demonstrate considerable serotonin transporter occupancy: implications for tapering SSRIs.

Authors:  Bryan B Shapiro
Journal:  Psychopharmacology (Berl)       Date:  2018-08-10       Impact factor: 4.530

Review 4.  Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.

Authors:  Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

Review 5.  Drug deprescription-withdrawal risk, prevention, and treatment.

Authors:  Madison K Bangert; Gabriel M Aisenberg
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-12-20

6.  Incidence and Timing of Taper/Posttherapy-Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder.

Authors:  Philip T Ninan; Jeff Musgnung; Michael Messig; Gina Buckley; Christine J Guico-Pabia; Tanya S Ramey
Journal:  Prim Care Companion CNS Disord       Date:  2015-02-05

Review 7.  [Tapering of antidementia drugs, antidepressants and antipsychotics in elderly patients : When possible, when not?]

Authors:  K Hager; T Temps; O Krause
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-06-06       Impact factor: 0.840

Review 8.  Selective Serotonin Reuptake Inhibitors and Operative Bleeding Risk: A Review of the Literature.

Authors:  Steven P Roose; Bret R Rutherford
Journal:  J Clin Psychopharmacol       Date:  2016-12       Impact factor: 3.153

9.  Pharmacotherapy of mood disorders and treatment discontinuation.

Authors:  Malcolm Lader
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?

Authors:  Fumihiko Okada
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.